BMO Capital Maintains Market Perform on Ionis Pharmaceuticals, Lowers Price Target to $54

Benzinga Newsdesk www.benzinga.com Negative 60.0%

Neg 60% Neu 0% Pos 0%

BMO Capital analyst David Lebowitz maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Market Perform and lowers the price target from $61 to $54.